Abstract
Introduction
Per-oral endoscopic myotomy (POEM) is effective in achalasia. The objective of this study was to evaluate the short-term clinical efficacy of POEM in non-achalasia esophageal motility disorders (NAEMD).
Patients and methods
Patients with NAEMD diagnosed by high-resolution manometry were included in a retrospective multicentric study. For each individual case, two controls paired on gender and age were matched: one with type I/II achalasia and one with type III achalasia. The clinical response, defined by an Eckardt score ≤ 3, was assessed at 3 and 6 months.
Results
Ninety patients (mean age 66 years, 57 men) were included, 30 patients with NAEMD (13 jackhammer esophagus, 6 spastic esophageal disorders, 4 nutcracker esophagus, and 7 esophagogastric junction obstruction), 30 patients with type I–II achalasia, and 30 patients with type III achalasia. The 3-month response rates were 80% (24/30), 90% (27/30), and 100% (30/30) in NAEMD, type I–II achalasia and type III achalasia, respectively (p < 0.01). Eckardt scores improved from preoperative baseline in all groups (median scores 2.0 after POEM vs. 6.5 before POEM, 1.3 vs. 7.2, and 0.5 vs. 6.1 in NAEMD, type I//I and Type III, respectively). No predictive factor of response was identified. In NAEMD patients, there was a significant improvement of dysphagia, regurgitation, and chest pain scores. The 6-month response rates were 63.2% (12/19), 95.5% (21/22), and 87.0% (20/23) in NAEMD, type I–II achalasia and type III achalasia, respectively (p = 0.03).
Conclusion
Although less effective than in achalasia, POEM is an effective treatment for NAEMD. Long-term follow-up data are needed to further confirm that POEM may be a valid treatment of NAEMD.
Similar content being viewed by others
References
Kahrilas PJ, Katzka D, Richter JE (2017) Clinical practice update: the use of per-oral endoscopic myotomy in achalasia: expert review and best practice advice from the AGA Institute. Gastroenterology 153:1205–1211
Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S (2010) Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 42:265–271
Haito-Chavez Y, Inoue H, Beard KW, Draganov PV, Ujiki M, Rahden BHA, Desai PN, Pioche M, Hayee B, Haji A, Saxena P, Reavis K, Onimaru M, Balassone V, Nakamura J, Hata Y, Yang D, Pannu D, Abbas A, Perbtani YB, Patel LY, Filser J, Roman S, Rivory J, Mion F, Ponchon T, Perretta S, Wong V, Maselli R, Ngamruengphong S, Chen YI, Bukhari M, Hajiyeva G, Ismail A, Pieratti R, Kumbhari V, Galdos-Cardenas G, Repici A, Khashab MA (2017) Comprehensive analysis of adverse events associated with per oral endoscopic myotomy in 1826 patients: an international multicenter study. Am J Gastroenterol 112:1267–1276
Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE, International High Resolution Manometry Working G (2015) The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 27:160–174
Zerbib F, Roman S (2015) Current therapeutic options for esophageal motor disorders as defined by the Chicago classification. J Clin Gastroenterol 49:451–460
Mion F, Marjoux S, Subtil F, Pioche M, Rivory J, Roman S, Zerbib F (2019) Botulinum toxin for the treatment of hypercontractile esophagus: results of a double-blind randomized sham-controlled study. Neurogastroenterol Motil 31:e13587
Vanuytsel T, Bisschops R, Farre R, Pauwels A, Holvoet L, Arts J, Caenepeel P, De Wulf D, Mimidis K, Rommel N, Tack J (2013) Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol 11(1115–1121):e1112
Sharata AM, Dunst CM, Pescarus R, Shlomovitz E, Wille AJ, Reavis KM, Swanstrom LL (2015) Peroral endoscopic myotomy (POEM) for esophageal primary motility disorders: analysis of 100 consecutive patients. J Gastrointest Surg 19:161–170
Teitelbaum EN, Dunst CM, Reavis KM, Sharata AM, Ward MA, DeMeester SR, Swanstrom LL (2018) Clinical outcomes five years after POEM for treatment of primary esophageal motility disorders. Surg Endosc 32:421–427
Khashab MA, Familiari P, Draganov PV, Aridi HD, Cho JY, Ujiki M, Rio Tinto R, Louis H, Desai PN, Velanovich V, Albeniz E, Haji A, Marks J, Costamagna G, Deviere J, Perbtani Y, Hedberg M, Estremera F, Martin Del Campo LA, Yang D, Bukhari M, Brewer O, Sanaei O, Fayad L, Agarwal A, Kumbhari V, Chen YI (2018) Peroral endoscopic myotomy is effective and safe in non-achalasia esophageal motility disorders: an international multicenter study. Endosc Int Open 6:E1031–e1036
Filicori F, Dunst CM, Sharata A, Abdelmoaty WF, Zihni AM, Reavis KM, Demeester SR, Swanstrom LL (2019) Long-term outcomes following POEM for non-achalasia motility disorders of the esophagus. Surg Endosc 33:1632–1639
Kane ED, Budhraja V, Desilets DJ, Romanelli JR (2019) Myotomy length informed by high-resolution esophageal manometry (HREM) results in improved per-oral endoscopic myotomy (POEM) outcomes for type III achalasia. Surg Endosc 33:886–894
Kumbhari V, Tieu A, Onimaru M, El Zein M, Teitelbaum E, Gitelis M, Modayil R, Hungness ES, Stravopoulos S, Shiwaku H, Kunda R, Chiu P, Saxena P, Messallam A, Inoue H, Khashab M (2015) Peroral endoscopy myotomy vs laparoscopic Heller myotomy for the treatment of type III achalasia in 75 patients: a multicenter comparative study. Endosc Int Open 3:E195–E201
Bechara R, Ikeda H, Inoue H (2016) Peroral endoscopic myotomy for Jackhammer esophagus: to cut or not to cut the lower esophageal sphincter. Endosc Int Open 4:E585–588
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
S. Roman: Medtronic, Diversatek, Mayoli Spindler, Biocodex, M. Barret: Olympus, Cook, V. Vitton: Ipsen, Biocodex, Sanofi, Kyowa Kirin, Medtronic, T. Wallenhorst: Cook Medical, Fujifilm, Abbvie, Ipsen, M. Pioche: Boston Scientific, Olympus, Norgine, S. Chaussade: Fujifilm, Olympus, J.-M. Gonzalez: Cook, Cousin, T. Ponchon: Olympus, F. Prat: Boston Scientific, Olympus, Pentax, M. Barthet: Boston Scientific, J. Vergniol: none, E. Chabrun: Olympus, Boston Scientific, Cook Medical, Life Partners Europe, F. Zerbib: Takeda, Allergan, Biocodex, Vifor Pharma, Mayoli Spindler, Ipsen, Abbott, Reckitt Benckiser, Alfasigma. L. Bernardot: no conflict of interest or financial ties to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bernardot, L., Roman, S., Barret, M. et al. Efficacy of per-oral endoscopic myotomy for the treatment of non-achalasia esophageal motor disorders. Surg Endosc 34, 5508–5515 (2020). https://doi.org/10.1007/s00464-019-07348-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-019-07348-y